

Development of innovative therapeutics that dually protect against bone erosion and inflammatory arthritis

MedPacto Inc.
MEDPACTO

IMMUNOLOGY	Preclinical
Product Type	Fc-fusion protein (hIgG1)
Indication	Systemic inflammatory arthritis
Target	TM4SF19 (Transmembrane 4 L six family member 19)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • MP2021 (hMoartLEL-Fc), a competitive binding inhibitor of Moart, binds to Integrin on the cell surface of M1-like macrophages that mediates inflammatory mechanisms. • MP2021 suppresses the excessive inflammatory responses, leading to the reprogramming into an M2-like macrophage with anti-inflammatory properties. • MP2021 inhibits the formation of multinucleated osteoclasts, thereby preventing inflammatory bone loss.
Competitiveness	First-in-Class
Development Stage	Preclinical
Route of Administration	Subcutaneous/ Intravenous